Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy

BACKGROUD: Cenegermin (Oxervate, Dompè Farmaceutici, Milan, IT), a recombinant human NGF, is a potentially healing new drug for neurotrophic keratopathy (NK), a rare but challenging disease affecting the cornea. To date, studies that evaluate its mid-term effect on corneal nerves and sensitivity are...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedrotti, Emilio, Bonacci, Erika, Chierego, Chiara, De Gregorio, Alessandra, Cozzini, Tiziano, Brighenti, Tommaso, Caldarella, Grazia, Pastore, Giovanlorenzo, Fasolo, Adriano, Marchini, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862484/
https://www.ncbi.nlm.nih.gov/pubmed/35189948
http://dx.doi.org/10.1186/s13023-022-02237-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862484/
https://www.ncbi.nlm.nih.gov/pubmed/35189948
http://dx.doi.org/10.1186/s13023-022-02237-5

Ejemplares similares